Chimeric proteins and methods for using the same

Details Chimeric proteins and methods for using the same Chimeric proteins and methods for using the same

2001-01-03

2009-08-04

Ouspenski, Ilia (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C514S002600, C514S012200

Reexamination Certificate

active

07569663

ABSTRACT:
Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell.

REFERENCES:
patent: 5851795 (1998-12-01), Linsley et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 6046310 (2000-04-01), Queen et al.
patent: 6632789 (2003-10-01), June
patent: 2003/0035816 (2003-02-01), Peach et al.
patent: 2003/0219863 (2003-11-01), Peach et al.
Rudert et al., Biochem. Biophys. Res. Commun., 1994, 2004: 1102-1110.
Timmer et al., J Pathol., 2002, 196: 125-134.
Hollenbaugh et al., J. Immunol. Methods, 1995, 188: 1-7.
Gessner et al., Ann. Hematol., 1998, 76: 231-248.
Wong et al., 2000, Mol. Biol. Cell, 11: 3109-3121.
Honda et al., 2003, Genes to Cells, 8: 481-491.
Huang et al., 2001, International Immunol., 13: 529-539.
Walczak et al., 1999, Nature Medicine, 5: 157-163.
Ashkenazi et al., 1999, J. Clin. Invest., 104: 155-162.
Gill et al., 1981, Horm. Metab. Res., 13: 603-609.
Gibson et al., 1999, J. Biol. Chem., 274: 17612-17618.
Jost et al., 2001, J. Invest. Dermatol., 116: 860-866.
Wang et al., 2002, Mol. Cell, 9: 411-421.
Greenwald et al., 2005, Annu. Rev. Immunol., 23: 515-548.
Dranitzki-Elhalel et al., Cellular Immunol., 2006, 239: 129-135 (reference provided by Applicant).
Lina Lu et al., “Blocking of the B7-CD28 Pathway Increases the Capacity of FasL (CD95L) Dendritic Cells to Kill Alloactivated T Cells”, Dendritic Cells in Fundamental and Clinical Immunology, Plenum Press, New York, 1997.
Nobuhiko Kayagaki et al., “Polymorphism of Murine Fas Ligand that Affects The Biological Activity”, Proc. Natl. Acad. Sci., vol. 94, pp. 3914-3919, Apr. 19, 1997.

Affiliated with

Also associated with

Rating

Chimeric proteins and methods for using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric proteins and methods for using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric proteins and methods for using the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4099503